The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback